Illumina, Inc. ILMN

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the launch of EpiSign METRIC 5-base, enabling laboratories to analyze DNA methylation data on the company's HiFi sequencing platform.

What a fantastic six months it’s been for Illumina. Shares of the company have skyrocketed 126%, hitting $273.47. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Key Stats for Illumina StockCurrent Price: $273. 90Target Price (Mid): ~$412Street Target: ~$203Potential Total Return: ~50%Annualized IRR: ~10% / yearWhat Happened?Illumina (ILMN) closed at $273.

Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The index removal comes at a time when Illumina’s momentum is already strong, with a 1-day share price return of 7.25%, a 30-day share price return of 21.82% and a year-to-date share price return of 103.87%. These feed into a 1-year total shareholder return of...

There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.

The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequencing, next-generation sequencing, chromosomal microarrays and personalized neonatal care. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key trends, technologies, segments, regional opportunities and leading companies, in

Key TakeawaysYear-Long Surge: Illumina stock has climbed 133% over the past year, closing at $240 on September 18, 2026, up from roughly $103 twelve months earlier. Street Split: Illumina stock carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $203 mean target now sits 15% below where shares trade, a reversal from a year ago when the target sat above the price.

AI, Advanced Sequencing and Precision Medicine Drive Genomics Opportunities Across Diagnostics, Drug Development and Preventive CareDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Genomics Market Forecast to Reach USD 188.7 Billion by 2035, Driven by Precision Healthcare and Sequencing Innovation The global genomics market was valued at USD 44.7 bi

Pharmacogenomics Expands as Multi-Gene Testing, Bioinformatics and Precision Diagnostics Drive Clinical AdoptionDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Pharmacogenomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Pharmacogenomics Market to Reach USD 15.4 Billion by 2035, Driven by Precision Medicine Adoption The global pharmacogenomics market was valued at USD 5.7 billion in 2025 and is proje